Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLE
Update: 2025-11-10
Description
Could a biologic that addresses uveitic macular edema (UME) change the treatment landscape for uveitis patients? Rahul Khurana, MD, joins us to review data from the MEERKAT and SANDCAT trials assessing vamikibart (Genentech/Roche) for UME. And Arshad Khanani, MD, MA, joins us to review the open-label extension study of GATHER2. What effect does avacincaptad pegol (Izervay, Astellas) have 2 years after the initial study was completed? Join us to hear details about these late-breaking presentations from AAO 2025.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
